MyFinsight
Home
Blog
About
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$604K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale and maturity ...
Stock-based compensation
Trade receivables, prepaid expen...
Depreciation
Negative Cash Flow Breakdown
Trade payables, accrued expenses...
Amortization of premium or disco...
Withholdings from exercise of op...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-06-30
Net loss
-3,585
-12,117
-14,366
Unrealized loss on cash equivalents
-
0
0
Depreciation
6
11
12
Stock-based compensation
474
1,016
1,292
Amortization of premium or discount on marketable securities
-18
-240
-538
Trade receivables, prepaid expenses and other assets and operating lease right-of-use assets
-202
-3,908
-306
Trade payables, accrued expenses, employee related obligations and other long-term liabilities
-1,160
-3,413
-8,896
Operating lease liabilities
0
-25
-74
Net cash used in operating activities
-4,081
-10,860
-22,264
Purchase of property and equipment
-
0
-
Proceeds from sale and maturity of marketable securities
4,700
20,450
47,850
Purchases of marketable securities
0
7,588
23,344
Net cash provided by investing activities
4,700
12,862
24,506
Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net
-15
-22
-121
Net cash used in financing activities
-15
-22
-121
Increase in cash and cash equivalents
604
1,980
2,121
Cash and cash equivalents at beginning of the period
24,027
19,926
-
Cash and cash equivalents at end of the period
24,631
24,027
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale and
maturity of marketable...
$4,700K
Net cash provided by
investing activities
$4,700K
Increase in cash and cash
equivalents
$604K
Canceled cashflow
$4,096K
Stock-based compensation
$474K
Trade receivables,
prepaid expenses and...
-$202K
Depreciation
$6K
Net cash used in
operating activities
-$4,081K
Net cash used in
financing activities
-$15K
Canceled cashflow
$682K
Net loss
-$3,585K
Trade payables,
accrued expenses,...
-$1,160K
Withholdings from exercise of
options and issuance of...
-$15K
Amortization of premium or
discount on marketable...
-$18K
Buy us a coffee